Bone mineral density, body composition and bone turnover in patients with congenital hypogonadotropic hypogonadism

International Journal of Andrology

Volumn 35, Issue 4, 2012, Pages 534-540

  Laitinen, E M ^a   Hero, M ^a   Vaaralahti, K ^a   Tommiska, J ^a   Raivio, T ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Body composition; Bone mineral density; Hypogonadotropic hypogonadism

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; CHORIONIC GONADOTROPIN; ESTRADIOL; ESTROGEN; FOLLITROPIN; ORAL CONTRACEPTIVE AGENT; PARATHYROID HORMONE; PROCOLLAGEN; PROCOLLAGEN TYPE 1 N TERMINAL PROPEPTIDE; PROGESTERONE; TESTOSTERONE; TESTOSTERONE ESTER; TESTOSTERONE UNDECANOATE; UNCLASSIFIED DRUG;

ADULT; AMENORRHEA; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY COMPOSITION; BODY FAT MASS; BODY HEIGHT; BODY MASS; BONE DENSITY; BONE STRUCTURE; BONE TURNOVER; CLINICAL ARTICLE; CROSS-SECTIONAL STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTRADIOL BLOOD LEVEL; FEMALE; FEMUR NECK; FOLLOW UP; HIP; HORMONE SUBSTITUTION; HUMAN; HYPOGONADOTROPIC HYPOGONADISM; KALLMANN SYNDROME; LEAN BODY WEIGHT; LOW DRUG DOSE; LUMBAR SPINE; MALE; MEDICAL HISTORY; MEDICAL RECORD REVIEW; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; TESTOSTERONE BLOOD LEVEL;

ABSORPTIOMETRY, PHOTON; ADULT; BIOLOGICAL MARKERS; BODY COMPOSITION; BODY MASS INDEX; BONE DENSITY; BONE RESORPTION; COLLAGEN TYPE I; ESTRADIOL; FEMALE; GONADAL STEROID HORMONES; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; MIDDLE AGED; OSTEOPOROSIS; PEPTIDE FRAGMENTS; PEPTIDES; PROCOLLAGEN; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; TESTOSTERONE; YOUNG ADULT;

EID: 84860782921     PISSN: 01056263     EISSN: 13652605     Source Type: Journal    
DOI: 10.1111/j.1365-2605.2011.01237.x     Document Type: Article

References (39)

1. Bachrach LK, Sills IN & Section on Endocrinology. (2011) Clinical report-bone densitometry in children and adolescents. Pediatrics 127, 189-194.
2. Behre HM, Kliesch S, Leifke E, Link TM & Nieschlag E. (1997) Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 82, 2386-2390.
3. Bhasin S, Storer TW, Berman N, Yarasheski KE, Clevenger B, Phillips J, Lee WP, Bunnell TJ & Casaburi R. (1997) Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 82, 407-413.
4. Bilezikian JP, Morishima A, Bell J & Grumbach MM. (1998) Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl J Med 339, 599-603.
5. Canale D, Vignali E, Golia F, Martino E, Pinchera A & Marcocci C. (2000) Effects of hormonal replacement treatment on bone mineral density and metabolism in hypogonadal patients. Mol Cell Endocrinol 161, 47-51.
6. Carani C, Qin K, Simoni M, Faustini-Fustini M, Serpente S, Boyd J, Korach KS & Simpson ER. (1997) Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med 337, 91-95.
7. Center JR, Bliuc D, Nguyen TV & Eisman JA. (2007) Risk of subsequent fracture after low-trauma fracture in men and women. JAMA 297, 387-394.
8. Christo K, Prabhakaran R, Lamparello B, Cord J, Miller KK, Goldstein MA, Gupta N, Herzog DB, Klibanski A & Misra M. (2008) Bone metabolism in adolescent athletes with amenorrhea, athletes with eumenorrhea, and control subjects. Pediatrics 121, 1127-1136.
9. Corona G, Monami M, Rastrelli G, Aversa A, Tishova Y, Saad F, Lenzi A, Forti G, Mannucci E & Maggi M. (2011) Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med 8, 272-283.
10. Crowley R, Wolfe I, Lock K & McKee M. (2011) Improving the transition between paediatric and adult healthcare: a systematic review. Arch Dis Child 96, 548-553.
11. De Rosa M, Paesano L, Nuzzo V, Zarrilli S, Del Puente A, Oriente P & Lupoli G. (2001) Bone mineral density and bone markers in hypogonadotropic and hypergonadotropic hypogonadal men after prolonged testosterone treatment. J Endocrinol Invest 24, 246-252.
12. Fernandez-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ et al. (2010) Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 95, 2560-2575.
13. Finkelstein JS, Klibanski A, Neer RM, Greenspan SL, Rosenthal DI & Crowley WF Jr. (1987) Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann Intern Med 106, 354-361.
14. Finkelstein JS, Klibanski A, Neer RM, Doppelt SH, Rosenthal DI, Segre GV & Crowley WF Jr. (1989) Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 69, 776-783.
15. Genant HK, Wu CY, van Kuijk C & Nevitt MC. (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8, 1137-1148.
16. Guo CY, Jones TH & Eastell R. (1997) Treatment of isolated hypogonadotropic hypogonadism effect on bone mineral density and bone turnover. J Clin Endocrinol Metab 82, 658-665.
17. Han TS & Bouloux PM. (2010) What is the optimal therapy for young males with hypogonadotropic hypogonadism? Clin Endocrinol (Oxf) 72, 731-737.
18. Jiao H, Arner P, Dickson SL, Vidal H, Mejhert N, Henegar C et al. (2011) Genetic association and gene expression analysis identify FGFR1 as a new susceptibility gene for human obesity. J Clin Endocrinol Metab 96, E962-E966.
19. Khosla S, Melton LJ 3rd & Riggs BL. (2011) The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed? J Bone Miner Res 26, 441-451.
20. Laitinen EM, Vaaralahti K, Tommiska J, Eklund E, Tervaniemi M, Valanne L & Raivio T. (2011) Incidence, phenotypic features and molecular genetics of Kallmann Syndrome in Finland. Orphanet J Rare Dis 6, 41.
21. Lorentzon M, Swanson C, Andersson N, Mellstrom D & Ohlsson C. (2005) Free testosterone is a positive, whereas free estradiol is a negative, predictor of cortical bone size in young Swedish men: the GOOD study. J Bone Miner Res 20, 1334-1341.
22. Morishima A, Grumbach MM, Simpson ER, Fisher C & Qin K. (1995) Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 80, 3689-3698.
23. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285, 785-795.
24. Popat VB, Calis KA, Vanderhoof VH, Cizza G, Reynolds JC, Sebring N, Troendle JF & Nelson LM. (2009) Bone mineral density in estrogen-deficient young women. J Clin Endocrinol Metab 94, 2277-2283.
25. Quinton R, Cheow HK, Tymms DJ, Bouloux PM, Wu FC & Jacobs HS. (1999) Kallmann's syndrome: is it always for life? Clin Endocrinol (Oxf) 50, 481-485.
26. Raivio T, Falardeau J, Dwyer A, Quinton R, Hayes FJ, Hughes VA et al. (2007) Reversal of idiopathic hypogonadotropic hypogonadism. N Engl J Med 357, 863-873.
27. Saggese G, Bertelloni S & Baroncelli GI. (1997) Sex steroids and the acquisition of bone mass. Horm Res 48(Suppl 5), 65-71.
28. Seeman E & Delmas PD. (2006) Bone quality - the material and structural basis of bone strength and fragility. N Engl J Med 354, 2250-2261.
29. Shaw ND, Seminara SB, Welt CK, Au MG, Plummer L, Hughes VA et al. (2011) Expanding the phenotype and genotype of female GnRH deficiency. J Clin Endocrinol Metab 96, E566-E576.
30. Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A et al. (2000) Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 85, 2670-2677.
31. Sonmez A, Haymana C, Bolu E, Aydogdu A, Tapan S, Serdar M et al. (2011) Metabolic syndrome and the effect of testosterone treatment in young men with congenital hypogonadotropic hypogonadism. Eur J Endocrinol 164, 759-764.
32. Sun L, Peng Y, Sharrow AC, Iqbal J, Zhang Z, Papachristou DJ et al. (2006) FSH directly regulates bone mass. Cell 125, 247-260.
33. Sun HD, Malabunga M, Tonra JR, DiRenzo R, Carrick FE, Zheng H et al. (2007) Monoclonal antibody antagonists of hypothalamic FGFR1 cause potent but reversible hypophagia and weight loss in rodents and monkeys. Am J Physiol Endocrinol Metab 292, E964-E976.
34. Trabado S, Maione L, Salenave S, Baron S, Galland F, Bry-Gauillard H et al. (2011) Estradiol levels in men with congenital hypogonadotropic hypogonadism and the effects of different modalities of hormonal treatment. Fertil Steril 95, 2324-2329. e1-3.
35. Turpeinen U, Linko S, Itkonen O & Hamalainen E. (2008) Determination of testosterone in serum by liquid chromatography-tandem mass spectrometry. Scand J Clin Lab Invest 68, 50-57.
36. Vanderschueren D, Vandenput L, Boonen S, Lindberg MK, Bouillon R & Ohlsson C. (2004) Androgens and bone. Endocr Rev 25, 389-425.
37. Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Berman N, Hull L & Swerdloff RS. (2004) Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 89, 2085-2098.
38. Yialamas MA, Dwyer AA, Hanley E, Lee H, Pitteloud N & Hayes FJ. (2007) Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 92, 4254-4259.
39. Yilmaz D, Ersoy B, Bilgin E, Gumuser G, Onur E & Pinar ED. (2005) Bone mineral density in girls and boys at different pubertal stages: relation with gonadal steroids, bone formation markers, and growth parameters. J Bone Miner Metab 23, 476-482.